Infliximab-dyyb (Zymfentra; Celltrion USA) is a subcutaneous version of Celltrion’s infliximab biosimilar for the maintenance treatment of adults with moderately to severely active ulcerative colitis and Crohn disease.
The approval of infliximab-dyyb as a maintenance therapy following IV infliximab for patients with moderately to severely active ulcerative colitis and Crohn disease was announced on October 22, 2023.
On October 5, Celltrion Healthcare Co. announced that it has signed a contract with Ventegra, a major U.S. Medical Benefits Manager (MBM) "who administers pharmacy benefits through its Pharmacy Services.
On October 5, Celltrion Healthcare Co. announced that it has signed a contract with Ventegra, a major U.S. Medical Benefits Manager (MBM) “who administers pharmacy benefits through its.